In skin cutaneous melanoma, GBP2 dampens development and metastasis by inhibiting Wnt/β-catenin signaling, suggesting its utility as both a prognostic biomarker and anti-metastatic target (6). This evidence concerns the gene GBP2 and cutaneous melanoma.